[1] |
LUO Yi, JIANG Zhiwei.
Statistical consideration in the design of COVID-19 clinical trials in emergency
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 121-125.
|
[2] |
WANG Ao, CAI Jingjing, BAI Jianling, LIU Yue, YU Xuanxuan, CHEN Feng, ZHAO Yang, YU Hao.
Sample size estimation for average bioequivalence for highly variable drugs using two replicated crossover designs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 164-170.
|
[3] |
SHANG Feng, YU Chengkai, YANG Peng.
Bridging method of adjusted significance levels α' in the target region concerning superiority design for normal data distribution in MRCT
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 59-64.
|
[4] |
BAI Jianling, CHEN Mengkai, YU Hao, ZHAO Yang, CAI Jingjing, HUANG Lihong, JIANG Zhiwei, CHEN Feng.
Two methods for assessing consistency probability in multiregional clinical trials: a comparison study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1017-1021.
|
[5] |
LU Mengjie, LIU Yuxiu, LU Guangming, ZHANG Longjiang, HUANG Wei, GE Aichen.
Sample size calculation for single-arm OPC trials with multi endpoints
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 917-921.
|
[6] |
CHU Jiru, SHEN Jie.
Mechanism of the inhibition of apoptosis by survivin during high fluence low-power laser irradiation-induced apoptosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 640-644.
|
[7] |
WANG Yafei, CHEN Feng, BAI Jianling, HUANG Lihong, YU Hao.
Statistical performance comparison of different simultaneous global development designs for targeted drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1127-1132.
|
[8] |
CHEN Lin, LIU Yu-xiu, MIAO Hua-zhang.
Statistical performance comparison of different design methods of targeted clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 399-403.
|
[9] |
GUO Yang, JIANG Zhi-wei, XIA Jie-lai, WANG Yu-kun.
Statistical considerations of group sequential design in oncology clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 175-180.
|
[10] |
WEN Shi-mei, CHEN Yun-fei, LIU Hua.
SAS programming for sample size and power calculation of measurement data in non-inferior trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 51-54.
|
[11] |
CHENG Qi, LIU Yu-xiu, CHEN Lin, LIU Li-xia.
Exact method of sample size calculation and statistical inference in single-arm clinical trials with objective performance criteria
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 517-522.
|
[12] |
LI Chan-juan, JIANG Zhi-wei, WANG Rui, XIA Jie-lai.
Sample size estimation in randomized controlled drug clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1132-1136.
|
[13] |
LIU Yu-xiu, XU Xiao-li, ZHENG Jun.
Sample size estimation and hypothesis testing of assessing equivalence/noninferiority for paired binary data
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(3): 299-302.
|
[14] |
LU Jing-jing, CHEN Feng, CUI Yong-chun, WANG Shou-cang, ZHANG Ai-min, LI Ren-peng, XU Jin-ke.
Estimation of sample size in individual bioequivalence
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 204-207.
|
[15] |
HE Ying-chun, ZHENG Qing-shan.
Clinical trial design of compound lisinopril in treatment essential hypertension in Chinese patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(12): 1427-1429.
|